| scholarly article | Q13442814 |
| P2093 | author name string | Margaret R Hammerschlag | |
| Patricia M Roblin | |||
| Andrei Kutlin | |||
| P2860 | cites work | A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae | Q73255362 |
| Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall | Q73284558 | ||
| Effect of clarithromycin and azithromycin on production of cytokines by human monocytes | Q77377948 | ||
| The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 | ||
| Chlamydia pneumoniae and atherosclerosis. | Q33534714 | ||
| In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae | Q33701390 | ||
| Chlamydia pneumoniae, monocyte activation, and azithromycin in coronary heart disease | Q33762172 | ||
| Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: design issues | Q33762181 | ||
| Growth in vascular cells and cytokine production by Chlamydia pneumoniae | Q33935046 | ||
| Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro | Q33980950 | ||
| Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers | Q35136913 | ||
| Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells | Q35488540 | ||
| In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae | Q35885610 | ||
| Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model | Q37873353 | ||
| Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae | Q37876262 | ||
| Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells | Q37877073 | ||
| In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model | Q37877849 | ||
| Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamyd | Q37878769 | ||
| Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children | Q37879880 | ||
| Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro | Q37880162 | ||
| Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. | Q37881682 | ||
| Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction | Q37882420 | ||
| Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response | Q37884521 | ||
| Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. | Q37886996 | ||
| Persistent infection with Chlamydia pneumoniae following acute respiratory illness | Q37893923 | ||
| Anti-inflammatory activity of macrolide antibiotics | Q40911052 | ||
| Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae | Q42729698 | ||
| Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events | Q43429735 | ||
| Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy | Q44262048 | ||
| Effect of antiserum and antibiotics on persistent infection of HeLa cells with meningopneumonitis virus. | Q45718359 | ||
| Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin | Q47330818 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clarithromycin | Q118551 |
| azithromycin | Q165399 | ||
| levofloxacin | Q424193 | ||
| Chlamydia pneumoniae | Q62869737 | ||
| P304 | page(s) | 409-412 | |
| P577 | publication date | 2002-02-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model | |
| P478 | volume | 46 |
| Q35917262 | Advances in the management of Chlamydia pneumoniae infections |
| Q38085248 | Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis. |
| Q34784830 | Antibiotic resistance in Chlamydiae |
| Q24645975 | Chlamydia inhibit host cell apoptosis by degradation of proapoptotic BH3-only proteins |
| Q34481798 | Chlamydia pneumoniae infection enhances cellular proliferation and reduces steroid responsiveness of human peripheral blood mononuclear cells via a tumor necrosis factor-alpha-dependent pathway |
| Q35014062 | Chlamydia pneumoniae resists antibiotics in lymphocytes |
| Q34434848 | Chlamydia trachomatis survival in the presence of two fluoroquinolones (lomefloxacin versus levofloxacin) in patients with chronic prostatitis syndrome |
| Q33760632 | Chlamydial zoonoses |
| Q37607163 | Combination therapy with ampicillin and azithromycin in an experimental pneumococcal pneumonia is bactericidal and effective in down regulating inflammation in mice |
| Q34781808 | Comparison of quantitative and semiquantitative enzyme-linked immunosorbent assays for immunoglobulin G against Chlamydophila pneumoniae to a microimmunofluorescence test for use with patients with respiratory tract infections |
| Q37869973 | Differential expression of genes encoding membrane proteins between acute and continuous Chlamydia pneumoniae infections |
| Q37850156 | Effects of coadministration of natural polyphenols with doxycycline or calcium modulators on acute Chlamydia pneumoniae infection in vitro |
| Q33883747 | Frequency of spontaneous mutations that confer antibiotic resistance in Chlamydia spp. |
| Q37866577 | Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae |
| Q28069433 | Lead Discovery Strategies for Identification of Chlamydia pneumoniae Inhibitors |
| Q35688156 | Macrolide antibiotics: current and future uses |
| Q37959271 | Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. |
| Q37869457 | Monitoring intracellular replication of Chlamydophila (Chlamydia) pneumoniae in cell cultures andcomparing clinical samples by real-time PCR |
| Q37844575 | Persistent C. pneumoniae infection in atherosclerotic lesions: rethinking the clinical trials |
| Q37864413 | Silencing or permanent activation: host-cell responses in models of persistent Chlamydia pneumoniae infection |
| Q88248631 | Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides |
| Q36757925 | The role of antibiotics in asthma |
| Q37849351 | Treatment of chlamydial infections |
Search more.